Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 13:18Maria Elisa Mancuso: EHC 2026 Opens with Focus on Haemophilia Care, Access and Rare Disorders
-
Oct 4, 2026, 13:16Anita Brikman: Inside the Plasma Donation Journey
-
Oct 4, 2026, 13:13Overcoming FVIII Inhibitors With Efanesoctocog Alfa – JTH
-
Oct 4, 2026, 13:04World Federation of Hemophilia Invites Global Community to GPAS 2026
-
Oct 4, 2026, 12:57Tooth Extraction in Patients with Haemophilia – RPTH Journal
-
Oct 4, 2026, 12:36Maia Meier: Advancing Hemophilia Care in Nepal – Project Elevate Her Visits Civil Service Hospital
-
Oct 4, 2026, 12:30Shailaja Kota Amplifies World Inherited Blood Disorders Month and Global Action Network’s Call to Action
-
Oct 4, 2026, 12:21Davide Pallucci: How Altered Platelet Metabolism Can Drive Changes in their Reactivity in Human and Mouse MASLD
-
Oct 4, 2026, 11:02Stimuli-Induced Remodeling of the Platelet Lipidome in Pulmonary Embolism – ESC